NPC
MCID: NSP012
MIFTS: 62

Nasopharyngeal Carcinoma (NPC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Oral diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Nasopharyngeal Carcinoma

MalaCards integrated aliases for Nasopharyngeal Carcinoma:

Name: Nasopharyngeal Carcinoma 57 11 19 58 75 28 53 5 14 38 71
Malignant Neoplasm of Nasopharynx 11 71 31
Nasopharyngeal Carcinoma 1 57 12
Nasopharyngeal Neoplasms 43 71
Nasopharyngeal Cancer 57 19
Nasopharynx Carcinoma 11 14
Npc 57 16
Squamous Cell Carcinoma of the Nasopharynx 58
Malignant Nasopharyngeal Tumor 11
Carcinoma of Nasopharynx 11
Nasopharyngeal Neoplasm 16
Cancer of Nasopharynx 71
Nasopharynx Cancer 11
Npca 57

Characteristics:


Inheritance:

Multigenic/multifactorial 58

Prevelance:

1-9/1000000 (China, Europe, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-9/100000 (Europe, Malta) 58

Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare respiratory diseases


External Ids:

Disease Ontology 11 DOID:9261
OMIM® 57 607107
MeSH 43 D009303
NCIt 49 C9321
MESH via Orphanet 44 C538339
ICD10 via Orphanet 32 C11.0 C11.1 C11.2 more
UMLS via Orphanet 72 C0153392 C0238301 C2931822
Orphanet 58 ORPHA150
MedGen 40 C2931822
SNOMED-CT via HPO 69 126680004
ICD11 33 294167983
UMLS 71 C0027439 C0153392 C0153393 more

Summaries for Nasopharyngeal Carcinoma

OMIM®: 57 Nasopharyngeal carcinoma (NPC, NPCA) is a multifactorial malignancy associated with both genetic and environmental factors. The cancer arises from the epithelium of the nasopharynx. The Epstein-Barr virus has been implicated (Tse et al., 2009). (607107) (Updated 08-Dec-2022)

MalaCards based summary: Nasopharyngeal Carcinoma, also known as malignant neoplasm of nasopharynx, is related to squamous cell carcinoma and burkitt lymphoma, and has symptoms including headache, tinnitus and rhinorrhea. An important gene associated with Nasopharyngeal Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are miRNAs involved in DNA damage response and let-7 inhibition of ES cell reprogramming. The drugs Fentanyl and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, t cells and skin, and related phenotype is neoplasia of the nasopharynx.

Disease Ontology: 11 A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or throat, where the nasal passages and auditory tubes join the remainder of the upper respiratory tract.

GARD: 19 Nasopharyngeal carcinoma (NPC) is a tumor arising from the epithelial cells that cover the surface and line the nasopharynx.

Orphanet: 58 Nasopharyngeal carcinoma (NPC) is a tumor arising from the epithelial cells that cover the surface and line the nasopharynx.

Wikipedia: 75 Nasopharyngeal carcinoma (NPC), or nasopharynx cancer, is the most common cancer originating in the... more...

Related Diseases for Nasopharyngeal Carcinoma

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 2 Nasopharyngeal Carcinoma 3

Diseases related to Nasopharyngeal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 860)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.8 TP53 NEAT1 MALAT1 HOTAIR H19 FOXCUT
2 burkitt lymphoma 31.8 TP53 PVT1 NFKBIA NEAT1
3 squamous cell carcinoma, head and neck 31.7 TP53 NFKBIA MIR29C HOTAIR H19
4 b-cell lymphoma 31.6 TP53 PVT1 NFKBIA MALAT1 HOTAIR
5 osteogenic sarcoma 31.4 XIST TP53 PVT1 NEAT1 MEG3 MALAT1
6 gastric cancer 31.4 XIST TP53 PVT1 NPTN-IT1 NFKBIA NEAT1
7 esophageal cancer 31.2 TP53 PVT1 MIR100 MEG3 MALAT1 HOTAIR
8 thyroid carcinoma 31.1 PVT1 NEAT1 MALAT1 LINC00312 HOTAIR H19
9 breast cancer 31.0 XIST TP53 PVT1 NFKBIA NEAT1 MIR29C
10 lung cancer susceptibility 3 31.0 TP53 NPTN-IT1 MEG3 MALAT1 LINC-ROR HOTAIR
11 cervical cancer 30.9 TP53 PVT1 NPTN-IT1 NEAT1 MEG3 MALAT1
12 hepatocellular carcinoma 30.9 XIST TP53 PVT1 NPTN-IT1 NFKBIA NEAT1
13 retinitis pigmentosa 11 30.9 XIST TP53 PVT1 NEAT1 HOTAIR CDKN2B-AS1
14 myeloma, multiple 30.8 TP53 PVT1 NFKBIA MEG3 MALAT1 HOTAIR
15 lung cancer 30.8 XIST TP53 PVT1 PCAT7 NFKBIA NEAT1
16 small cell cancer of the lung 30.7 TP53 MALAT1 HOTAIR
17 laryngeal squamous cell carcinoma 30.7 TP53 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
18 tongue carcinoma 30.7 TP53 MIR100 MALAT1
19 colorectal cancer 30.6 XIST TP53 PVT1 NPTN-IT1 NFKBIA NEAT1
20 pituitary adenoma 30.6 MEG3 MALAT1 HOTAIR H19
21 neuroblastoma 30.6 TP53 MIR29C MEG3 MALAT1 HOTAIR H19
22 esophagus squamous cell carcinoma 30.6 XIST PVT1 NPTN-IT1 MEG3 MALAT1 LINC00460
23 bladder cancer 30.5 XIST TP53 PVT1 MIR29C MIR100 MEG3
24 glioblastoma 30.5 XIST TP53 MEG3 MALAT1 HOTAIR H19
25 renal cell carcinoma, nonpapillary 30.5 TP53 PVT1 NPTN-IT1 MIR29C MIR100 MEG3
26 ovarian cancer 30.5 XIST TP53 PVT1 NFKBIA NEAT1 MIR29C
27 glioma 30.5 TP53 PVT1 NEAT1 MEG3 MALAT1 HOTAIR
28 oral squamous cell carcinoma 30.5 NEAT1 MIR100 MEG3 MALAT1 HOTAIR H19
29 pancreatic cancer 30.5 XIST TP53 PVT1 NFKBIA NEAT1 MIR100
30 melanoma 30.5 XIST TP53 PVT1 MIR100 MEG3 MALAT1
31 tongue squamous cell carcinoma 30.5 TP53 MEG3 MALAT1 AFAP1-AS1
32 high grade glioma 30.4 XIST TP53 PVT1 NEAT1 MEG3 MALAT1
33 thyroid cancer, nonmedullary, 1 30.4 TP53 PVT1 NEAT1 MEG3 MALAT1 LINC-ROR
34 leukemia, chronic myeloid 30.4 TP53 NFKBIA MEG3 HOTAIR H19
35 lung squamous cell carcinoma 30.3 TP53 PVT1 NPTN-IT1 MEG3
36 prostate cancer 30.2 XIST TP53 PVT1 PCAT7 NFKBIA NEAT1
37 leukemia, acute myeloid 30.2 TP53 MEG3 MALAT1 HOTAIR CDKN2B-AS1
38 nasopharyngeal carcinoma 3 11.7
39 nasopharyngeal carcinoma 2 11.7
40 lymphoepithelioma-like carcinoma 11.1
41 mucositis 11.0
42 head and neck cancer 10.9
43 aplasia of lacrimal and salivary glands 10.9
44 neutropenia 10.8
45 nasopharyngitis 10.8
46 factor vii deficiency 10.7
47 otitis media 10.7
48 osteonecrosis 10.7
49 rhabdomyosarcoma 2 10.7
50 viral infectious disease 10.7

Comorbidity relations with Nasopharyngeal Carcinoma via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Nasopharyngeal Carcinoma:



Diseases related to Nasopharyngeal Carcinoma

Symptoms & Phenotypes for Nasopharyngeal Carcinoma

Human phenotypes related to Nasopharyngeal Carcinoma:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasia of the nasopharynx 30 HP:0100630

Clinical features from OMIM®:

607107 (Updated 08-Dec-2022)

UMLS symptoms related to Nasopharyngeal Carcinoma:


headache; tinnitus; rhinorrhea

Drugs & Therapeutics for Nasopharyngeal Carcinoma

Drugs for Nasopharyngeal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 299)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
3
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
6
Azithromycin Approved Phase 4 83905-01-5 447043
7
Cisplatin Approved Phase 4 15663-27-1 2767 5702198 441203
8
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
9
Rofecoxib Approved, Investigational, Withdrawn Phase 4 162011-90-7 5090
10 Anti-Bacterial Agents Phase 4
11 Analgesics, Opioid Phase 4
12 Narcotics Phase 4
13 Gastrointestinal Agents Phase 4
14 Anesthetics, Intravenous Phase 4
15 Anesthetics, General Phase 4
16 Erythromycin stearate Phase 4
17 Erythromycin Ethylsuccinate Phase 4
18 Erythromycin Estolate Phase 4
19 Antimitotic Agents Phase 4
20 Tubulin Modulators Phase 4
21 Cyclooxygenase 2 Inhibitors Phase 4
22
Fluorouracil Approved Phase 3 51-21-8 3385
23
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
24
Acyclovir Approved Phase 3 59277-89-3 2022
25
Oprelvekin Approved, Investigational Phase 3 145941-26-0
26
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
27
Epirubicin Approved Phase 3 56420-45-2 41867
28
Mitomycin Approved Phase 3 50-07-7 5746
29
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
30
Fluticasone Approved, Experimental Phase 3 90566-53-3 4659387 5311101
31
Benralizumab Approved, Investigational Phase 3 1044511-01-4
32
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
33
Tropisetron Approved, Investigational Phase 3 105826-92-4, 89565-68-4 656665
34
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
35
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
36
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
37
Nedaplatin Approved, Investigational Phase 3 95734-82-0
38
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
39
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
40
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
41
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
42
Ifosfamide Approved Phase 3 3778-73-2 3690
43
Etoposide Approved Phase 3 33419-42-0 36462
44
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
45
Mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7 4240 441336
46
Budesonide Approved Phase 3 51333-22-3 5281004 40000 63006
47
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
48
Nimotuzumab Investigational Phase 3 780758-10-3
49
Palifosfamide Investigational Phase 3 31645-39-3 100427
50 Endostatins Phase 3

Interventional clinical trials:

(show top 50) (show all 699)
# Name Status NCT ID Phase Drugs
1 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Unknown status NCT02293356 Phase 4 Nimotuzumab Injection
2 Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury After Therapy With Docetaxel and Cisplatin for Nasopharyngeal Carcinoma Unknown status NCT03069820 Phase 4 docetaxel and cisplatin
3 A Prospective, Randomized Controlled Open Research About the Impact of Nutritional Support on the Radiation Tolerance and Clinical Outcomes for Local Advanced Nasopharyngeal Carcinoma Patients Unknown status NCT02948699 Phase 4
4 A Comparison of Oral Controlled-release Morphine With Transdermal Fentanyl in Nasopharyngeal Cancer Patients With Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy Unknown status NCT04292990 Phase 4 Fentanyl;Morphine
5 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
6 Azithromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT04454151 Phase 4 Azithromycin Tablets
7 Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough. Unknown status NCT02175914 Phase 4 Erythromycin
8 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
9 Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-keratinized Squamous Cell Carcinoma of Nasopharynx Completed NCT00772681 Phase 4 docetaxel and cisplatin
10 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP) Terminated NCT00140894 Phase 4 MK0966; rofecoxib / Duration of Treatment: 24 weeks;Comparator: placebo / Duration of Treatment: 24 weeks
11 A Prospective,Randomized,Controlled,Multicenter,Phase III Study of Stage Ⅲ Study of Gemcitabine Plus Cisplatin With or Without Endostatin to the Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
12 Induction Chemotherapy of Docetaxel, Cisplatin and Xeloda in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT02786641 Phase 3 Docetaxel;Cisplatin 1;Xeloda;Cisplatin 2
13 Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era Unknown status NCT02633202 Phase 3 Cisplatin
14 Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy With or Without Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01872962 Phase 3 gemcitabine and cisplatin (Induction chemotherapy)
15 Intensity Modulated Radiotherapy Plus Cisplatin Versus Intensity Modulated Radiotherapy in Patients With Stage 2 Nasopharyngeal Carcinoma: A Phase 3 Multicenter, Open-label, Randomized, Non-inferior Clinical Trial Unknown status NCT03068936 Phase 3 Cisplatin
16 A Multicenter Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
17 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated Radiotherapy With or Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
18 Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
19 Multicentre Randomization Clinic Trial of Systemic Chemotherapy Combined With Loco-regional Radiotherapy vs. Chemotherapy Alone for Initially Untreated Distant Metastatic Nasopharyngeal Carcinoma With Chemosensitivity Unknown status NCT02111460 Phase 3
20 Fine Needle Aspiration of Retropharyngeal Lymph Node Guided by Endoscopic Ultrasound for the Diagnosis of Patients With Suspected Recurrent Nasopharyngeal Carcinoma Unknown status NCT03006588 Phase 2, Phase 3
21 A Multicenter Trial Comparing Neoadjuvant Chemotherapy Followed by CCRT v.s. CCRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
22 A Single Center, Open-label, Randomized Controlled Clinical Trial on the Early and Whole Course Nutritional Support by Nutren® Optimum During Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT03344068 Phase 2, Phase 3 Chemotherapy
23 A Randomized Phase III Non-inferiority Study of Induction Chemotherapy Followed by IMRT Alone Versus Induction Chemotherapy Followed by IMRT Plus Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT02434614 Phase 3 Docetaxel,Cisplatin,Fluorouracil;Cisplatin
24 Randomized Phase III Study in EBV Positive Locally Advanced Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug Unknown status NCT03656965 Phase 3 Acyclovir 800 MG
25 Phase III Randomized Trial of Anlotinib Plus Gemcitabine/Cisplatin Vesus Placebo Plus Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma Unknown status NCT03601975 Phase 3 Gemcitabine/Cisplatin
26 Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02500940 Phase 3 Cisplatin;Fluorouracil;Leucovorin
27 A Phase III Randomized Trial of Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage Unknown status NCT03403829 Phase 3 Gemcitabine
28 A Multicenter, Randomized Controlled Phase III Clinical Trial of GP Induction Chemotherapy With TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Nasopharyngeal Carcinoma Unknown status NCT03604965 Phase 3 GP+CCRT;TPF+CCRT
29 The Effect of Celecoxib on Concurrent Chemoradiation With Weekly Nedaplatin in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
30 Phase III Randomized Trial of Immediate Adjuvant Chemotherapy or Delayed Salvage Chemotherapy in Nasopharyngeal Carcinoma Patients With Post-radiation Detectable Plasma EBV DNA Unknown status NCT02363400 Phase 3 MEP
31 Prospective Randomized Trial Comparing Induction Chemotherapy Plus Concurrent Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01245959 Phase 3 Docetaxel, cisplatin and fluorouracil
32 Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Following High-dose Cisplatin in Nasopharyngeal Carcinoma Patients:a Randomized Phase 3 Trial Unknown status NCT02933099 Phase 3 Aprepitant+palonosetron+dexamethasone;palonosetron+dexamethasone
33 A Randomized Phase III Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT02944708 Phase 3 Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2
34 A Multicenter, Prospective, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) Unknown status NCT02907710 Phase 3 Endostar;DDP
35 A Multicenter Trial Evaluating the Efficacy and Safety of Nedaplatin Plus Docetaxel in Neoadjuvant Chemotherapy Followed by Nedaplatin in Concurrent Chemoradiation for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel
36 Cisplatin and 5-fluorouracil(PF) or Docetaxel,Cisplatin and 5-fluorouracil (TPF) Neoadjuvant Chemotherapy With Chemoradiation Therapy for Locally Advanced Nasopharyngeal Carcinoma--A Randomised Prospective Multicenter Phase 3 Study Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
37 Multicenter Phase III Study of Intensity-modulated Radiotherapy Alone Compared to Intensity-modulated Radiotherapy Combined Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma Unknown status NCT01817023 Phase 3 Cisplatin
38 A Randomized Phase III Study of Concurrent Weekly Nedaplatin or Cisplatin With IMRT in NPC Patients Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
39 The Open and Multi-center Phase III Clinical Study of Interleukin-11 in the Prevention and Treatment of Radioactive Oral Mucitis Unknown status NCT03720340 Phase 3 Recombinant Human Interleukin-11;Saline
40 MULTICENTRIC INTERNATIONAL RANDOMIZED PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE. Unknown status NCT00180973 Phase 3 Hydroxyurea
41 A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
42 Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
43 Standard Radiotherapy Versus Concurrent Chemo-Radiotherapy Followed by Adjuvant Chemotherapy for Locally Advanced (Non-Metastatic) Nasopharyngeal Cancer Unknown status NCT00003637 Phase 3 cisplatin;fluorouracil
44 Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma Completed NCT00379262 Phase 3 Capecitabine;Adjuvant chemotherapy using PF (5-Fluorouracil );Induction chemotherapy using PF (5-Fluorouracil)
45 Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial Completed NCT02143388 Phase 3 IMRT combine with cisplatin concurrent chemotherapy;IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
46 A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients Completed NCT02578641 Phase 3 combination IV gemcitabine and IV carboplatin (AUC2)
47 Late-Course Accelerated Hyperfractionated IMRT Versus Conventionally Fractionated IMRT in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective Randomized Clinical Trial Completed NCT00778908 Phase 2, Phase 3 Concomitant cisplatin chemotherapy
48 Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy With Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC). Completed NCT02012062 Phase 3 TPF neoadjuvant chemotherapy;Concurrent chemotherapy with cisplatin during radiotherapy;Concurrent nimotuzumab during radiotherapy
49 The Multicenter Randomized Phase 3 Trial of Individualized Elective Neck Irradiation Based on MRI in Patients With Nasopharyngeal Carcinoma Completed NCT02642107 Phase 3
50 A Multicenter Phase III Trial Comparing Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Stage IV Nasopharyngeal Carcinoma (NPC) Completed NCT00201396 Phase 3 Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin

Search NIH Clinical Center for Nasopharyngeal Carcinoma

Cochrane evidence based reviews: nasopharyngeal neoplasms

Genetic Tests for Nasopharyngeal Carcinoma

Genetic tests related to Nasopharyngeal Carcinoma:

# Genetic test Affiliating Genes
1 Nasopharyngeal Carcinoma 28 TP53

Anatomical Context for Nasopharyngeal Carcinoma

Organs/tissues related to Nasopharyngeal Carcinoma:

MalaCards : Lymph Node, T Cells, Skin, Temporal Lobe, Salivary Gland, Nk Cells, Liver

Publications for Nasopharyngeal Carcinoma

Articles related to Nasopharyngeal Carcinoma:

(show top 50) (show all 16913)
# Title Authors PMID Year
1
An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. 62 57 5
1631151 1992
2
The genomic landscape of nasopharyngeal carcinoma. 62 57
24952746 2014
3
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. 62 57
20512145 2010
4
Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. 62 57
19664746 2009
5
A functional variant in the transcriptional regulatory region of gene LOC344967 cosegregates with disease phenotype in familial nasopharyngeal carcinoma. 62 57
16423998 2006
6
Association of PLUNC gene polymorphisms with susceptibility to nasopharyngeal carcinoma in a Chinese population. 62 57
15689457 2005
7
A rare polymorphism of the COX7B2 gene in a Cantonese family with nasopharyngeal carcinoma. 62 57
15623157 2004
8
Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. 62 57
12118254 2002
9
Familial nasopharyngeal carcinoma. 62 57
6609336 1984
10
Familial clustering of nasopharyngeal carcinoma. 62 57
7191767 1980
11
Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. 62 46
19739117 2010
12
Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from southeastern Asia. 57
7729941 1995
13
Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. 53 62
20124221 2010
14
[Tumor-targeted human telomerase reverse transcriptase promoter/tk gene therapy against human nasopharyngeal carcinoma cells in vitro]. 53 62
20423828 2010
15
Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. 53 62
20412566 2010
16
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. 53 62
20053927 2010
17
Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. 53 62
20398418 2010
18
Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells. 53 62
20036222 2010
19
Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. 53 62
20338061 2010
20
Indole-3-carbinol inhibits nasopharyngeal carcinoma. 53 62
20335513 2010
21
[Study on the relationship between TK gene regulated by enhanced suicide gene vector and telomerase activity in nasopharyngeal carcinoma cells]. 53 62
20422982 2010
22
Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells. 53 62
20109337 2010
23
Bax inhibitor-1 mediates apoptosis-resistance in human nasopharyngeal carcinoma cells. 53 62
19579059 2010
24
Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. 53 62
19628018 2010
25
A case-control and a family-based association study revealing an association between CYP2E1 polymorphisms and nasopharyngeal carcinoma risk in Cantonese. 53 62
19805575 2009
26
Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. 53 62
19816982 2009
27
Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. 53 62
20042089 2009
28
PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. 53 62
19735264 2009
29
[Expression of HSP70/HSP27 protein in residual lesion after NPC radiotherapy]. 53 62
19952398 2009
30
[Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression]. 53 62
20387494 2009
31
[Induced RAS association domain family gene 1A gene expression by arsenic trioxide in nasopharyngeal carcinoma cell]. 53 62
20079060 2009
32
LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells. 53 62
19860880 2009
33
Role of p38 MAPKs in hypericin photodynamic therapy-induced apoptosis of nasopharyngeal carcinoma cells. 53 62
19496992 2009
34
ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway. 53 62
19698176 2009
35
IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients. 53 62
19551836 2009
36
[The relationship between the expression of EGFR NF-kappaB and radiosensitivity in human nasopharyngeal carcinoma]. 53 62
19947250 2009
37
Regulation of RASSF1A in nasopharyngeal cells and its response to UV irradiation. 53 62
19450668 2009
38
[Expression of E-cadherin and P(120ctn) in nasopharyngeal carcinoma and their relationship]. 53 62
19894558 2009
39
[Matrine enhances the cytotoxic sensitivity of ABCG2high nasopharyngeal carcinoma cells to natural killer cells by inducing high expression of NKG2D receptor ligands]. 53 62
19620045 2009
40
[Association of nasopharyngeal carcinoma risk with cytochrome P450 CYP1A1 gene polymorphisms]. 53 62
19954069 2009
41
Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. 53 62
19429479 2009
42
Curcuminoids suppress the growth of pharynx and nasopharyngeal carcinoma cells through induced apoptosis. 53 62
19317462 2009
43
Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma. 53 62
19360294 2009
44
Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. 53 62
19132724 2009
45
[Association of CXCR4 and SDF-1alpha with organ-specific metastasis of nasopharyngeal carcinoma]. 53 62
19615279 2009
46
Nasopharyngeal carcinoma in Brunei Darussalam: low incidence among the Chinese and an evaluation of antibodies to Epstein-Barr virus antigens as biomarkers. 53 62
19421680 2009
47
GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an evidence-based meta-analysis. 53 62
19338664 2009
48
Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. 53 62
19221469 2009
49
Dual silencing of epidermal growth factor and insulin-like growth factor 1 receptors significantly limits growth of nasopharyngeal carcinoma in nude mice. 53 62
18452630 2009
50
[Association of the T1270533G polymorphism in GSTM1 gene coding region with susceptibility to nasopharyngeal carcinoma in a Chinese population]. 53 62
19218107 2009

Variations for Nasopharyngeal Carcinoma

ClinVar genetic disease variations for Nasopharyngeal Carcinoma:

5 (show all 11)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Pathogenic
12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
2 TP53 NM_000546.6(TP53):c.559+1G>A SNV Pathogenic
428908 rs1131691042 GRCh37: 17:7578370-7578370
GRCh38: 17:7675052-7675052
3 TP53 NM_000546.6(TP53):c.524G>A (p.Arg175His) SNV Pathogenic
12374 rs28934578 GRCh37: 17:7578406-7578406
GRCh38: 17:7675088-7675088
4 TP53 NM_000546.6(TP53):c.96+1G>T SNV Pathogenic
482212 rs1131691003 GRCh37: 17:7579699-7579699
GRCh38: 17:7676381-7676381
5 TP53 NM_000546.6(TP53):c.839G>C (p.Arg280Thr) SNV Pathogenic
12368 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
6 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Pathogenic
12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
7 TP53 NM_000546.6(TP53):c.799C>T (p.Arg267Trp) SNV Likely Pathogenic
141764 rs55832599 GRCh37: 17:7577139-7577139
GRCh38: 17:7673821-7673821
8 TP53 NM_000546.6(TP53):c.466C>T (p.Arg156Cys) SNV Uncertain Significance
127810 rs563378859 GRCh37: 17:7578464-7578464
GRCh38: 17:7675146-7675146
9 TP53 NM_000546.6(TP53):c.461G>A (p.Gly154Asp) SNV Uncertain Significance
237950 rs762846821 GRCh37: 17:7578469-7578469
GRCh38: 17:7675151-7675151
10 TP53 NM_000546.6(TP53):c.847C>T (p.Arg283Cys) SNV Uncertain Significance
127824 rs149633775 GRCh37: 17:7577091-7577091
GRCh38: 17:7673773-7673773
11 TP53 NM_000546.6(TP53):c.760A>G (p.Ile254Val) SNV Uncertain Significance
406605 rs746601313 GRCh37: 17:7577521-7577521
GRCh38: 17:7674203-7674203

Cosmic variations for Nasopharyngeal Carcinoma:

8 (show top 50) (show all 195)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143943797 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 13
2 COSM142560281 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 13
3 COSM144087106 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 13
4 COSM144310203 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 13
5 COSM142837352 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 13
6 COSM145017657 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 13
7 COSM105620276 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 13
8 COSM143156843 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 13
9 COSM122271559 TP53 skin,neck,carcinoma,squamous cell carcinoma c.347G>A p.R116Q 17:7674220-7674220 13
10 COSM106053189 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 13
11 COSM143370869 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 13
12 COSM111758576 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 13
13 COSM112253622 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 13
14 COSM93183630 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 13
15 COSM144013367 TP53 skin,neck,carcinoma,squamous cell carcinoma c.710G>A p.R237Q 17:7674220-7674220 13
16 COSM144651115 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 13
17 COSM87898351 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 13
18 COSM121875983 TP53 skin,neck,carcinoma,squamous cell carcinoma c.347G>A p.R116Q 17:7674220-7674220 13
19 COSM122734176 TP53 skin,neck,carcinoma,squamous cell carcinoma c.347G>A p.R116Q 17:7674220-7674220 13
20 COSM133256111 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1040C>T p.S347F 9:99146601-99146601 13
21 COSM97906895 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1016C>T p.S339F 9:99146601-99146601 13
22 COSM135128838 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1259C>T p.S420F 9:99146601-99146601 13
23 COSM97922732 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1247C>T p.S416F 9:99146601-99146601 13
24 COSM84678061 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 13
25 COSM98728167 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 13
26 COSM107058787 RARA skin,neck,carcinoma,squamous cell carcinoma c.1093C>T p.P365S 17:40356221-40356221 13
27 COSM98724263 RARA skin,neck,carcinoma,squamous cell carcinoma c.1432C>T p.P478S 17:40356221-40356221 13
28 COSM86828717 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 13
29 COSM98707797 RARA skin,neck,carcinoma,squamous cell carcinoma c.1369C>T p.P457S 17:40356221-40356221 13
30 COSM94496058 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 13
31 COSM133940534 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 13
32 COSM107373333 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 13
33 COSM130526023 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 13
34 COSM96948694 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 13
35 COSM97161923 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 13
36 COSM96619514 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 13
37 COSM97161935 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 13
38 COSM144156675 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.473G>A p.G158E 20:42352227-42352227 13
39 COSM96619533 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 13
40 COSM93273665 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 13
41 COSM96721565 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 13
42 COSM96835332 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 13
43 COSM142597931 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.454C>T p.S152L 20:42352239-42352239 13
44 COSM144156682 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.461C>T p.S154L 20:42352239-42352239 13
45 COSM97061657 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 13
46 COSM96835350 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 13
47 COSM96721578 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 13
48 COSM96948708 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 13
49 COSM93273656 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 13
50 COSM97061670 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 13

Copy number variations for Nasopharyngeal Carcinoma from CNVD:

6 (show all 41)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 72234 12 7764270 8036678 Duplication CLEC4C Nasopharyngeal cancer
2 72235 12 7764270 8036678 Duplication NANOG Nasopharyngeal cancer
3 72236 12 7764270 8036678 Duplication NANOGNB Nasopharyngeal cancer
4 72237 12 7764270 8036678 Duplication SLC2A14 Nasopharyngeal cancer
5 72238 12 7764270 8036678 Duplication SLC2A3 Nasopharyngeal cancer
6 126614 19 19848080 20497256 Deletion MIR1270 Nasopharyngeal cancer
7 126615 19 19848080 20497256 Deletion MIR1270 Nasopharyngeal cancer
8 126616 19 19848080 20497256 Deletion ZNF253 Nasopharyngeal cancer
9 126617 19 19848080 20497256 Deletion ZNF486 Nasopharyngeal cancer
10 126618 19 19848080 20497256 Deletion ZNF682 Nasopharyngeal cancer
11 126619 19 19848080 20497256 Deletion ZNF826P Nasopharyngeal cancer
12 126620 19 19848080 20497256 Deletion ZNF90 Nasopharyngeal cancer
13 126621 19 19848080 20497256 Deletion ZNF93 Nasopharyngeal cancer
14 132647 19 59423491 59445355 Deletion LILRA6 Nasopharyngeal cancer
15 171484 3 168801287 168851758 Amplification MECOM Nasopharyngeal cancer
16 171493 3 168867391 169381563 Amplification MECOM Nasopharyngeal cancer
17 177937 3 65166887 65190844 Deletion Nasopharyngeal cancer
18 197433 5 176843000 176857208 Deletion PDLIM7 Nasopharyngeal cancer
19 205127 6 121025447 121050579 Deletion Nasopharyngeal cancer
20 210827 6 31463047 31563588 Deletion HCG26 Nasopharyngeal cancer
21 210828 6 31463047 31563588 Deletion HCP5 Nasopharyngeal cancer
22 210829 6 31463047 31563588 Deletion MICA Nasopharyngeal cancer
23 210832 6 31463297 31559455 Deletion HCG26 Nasopharyngeal cancer
24 210836 6 31463297 31559455 Deletion HCP5 Nasopharyngeal cancer
25 210840 6 31463297 31559455 Deletion MICA Nasopharyngeal cancer
26 212636 6 4007991 32935606 Deletion PSMB9 Nasopharyngeal cancer
27 220654 7 140736 180194 Duplication CCDC146 Nasopharyngeal cancer
28 220655 7 140736 180194 Duplication Nasopharyngeal cancer
29 220656 7 140736 180194 Duplication Nasopharyngeal cancer
30 220657 7 140736 180194 Duplication PMS2P11 Nasopharyngeal cancer
31 220658 7 140736 180194 Duplication POMZP3 Nasopharyngeal cancer
32 222456 7 152200000 154700000 Duplication Nasopharyngeal cancer
33 222457 7 152200000 154700000 Duplication Nasopharyngeal cancer
34 222532 7 153118877 153284978 Duplication Nasopharyngeal cancer
35 222533 7 153118877 153284978 Duplication Nasopharyngeal cancer
36 224029 7 2721151 3758564 Duplication CARD11 Nasopharyngeal cancer
37 224030 7 2721151 3758564 Duplication GNA12 Nasopharyngeal cancer
38 227304 7 66680598 66860844 Deletion AR Nasopharyngeal cancer
39 229234 7 892539 3753994 Duplication Nasopharyngeal cancer
40 236340 8 15447307 15475846 Deletion TUSC3 Nasopharyngeal cancer
41 256863 9 9780222 9786577 Deletion Nasopharyngeal cancer

Expression for Nasopharyngeal Carcinoma

Search GEO for disease gene expression data for Nasopharyngeal Carcinoma.

Pathways for Nasopharyngeal Carcinoma

Pathways related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.63 TP53 MIR29C MIR100
2
Show member pathways
10.4 TP53 MIR29C

GO Terms for Nasopharyngeal Carcinoma

Biological processes related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of miRNA-mediated gene silencing GO:0060965 8.8 PVT1 NEAT1

Sources for Nasopharyngeal Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....